Printer Friendly
The Free Library
14,693,900 articles and books
Member login
User name  
Password 
 
Join us Forgot password?

Novel synthetic molecules boost immune response to HIV and prostate cancer.


Byline: ANI

Washington, Nov 6 (ANI): Synthetic molecules developed by researchers at Yale University could enhance the body's immune response immune response
n.
An integrated bodily response to an antigen, especially one mediated by lymphocytes and involving recognition of antigens by specific antibodies or previously sensitized lymphocytes.
 to HIV HIV (Human Immunodeficiency Virus), either of two closely related retroviruses that invade T-helper lymphocytes and are responsible for AIDS. There are two types of HIV: HIV-1 and HIV-2. HIV-1 is responsible for the vast majority of AIDS in the United States.  and HIV-infected cells, and prostate cancer prostate cancer, cancer originating in the prostate gland. Prostate cancer is the leading malignancy in men in the United States and is second only to lung cancer as a cause of cancer death in men.  cells.

The findings by Yale researchers could lead to novel therapeutic approaches for these diseases.

The molecules - called "antibody-recruiting molecule targeting HIV" (ARM-H) and "antibody-recruiting molecule targeting prostate cancer" (ARM-P ARM-P Associate in Risk Management for Public Entities (insurance industry certification) ) - work by binding simultaneously to an antibody already present in the bloodstream and to proteins on HIV, HIV-infected cells or cancer cells.

By coating these pathogens in antibodies, the molecules flag them as a threat and trigger the body's own immune response.

ARM-H molecules also bind to proteins on the outside of the virus and thus prevent healthy human cells from being infected.

"Instead of trying to kill the pathogens directly, these molecules manipulate our immune system to do something it wouldn't ordinarily do," said Dr. David Spiegel, the corresponding author of the study.

In contrast to other treatment options for HIV and cancer, the ARM-H and ARM-P molecules, which the team has begun testing in mice, are structurally simple, inexpensive to produce, and could in theory be taken in pill form, said Spiegel.

And because they are unlikely to target essential biological processes in the body, the side effects could be smaller, he said.

"This is an entirely new approach to treating these two diseases, which are extraordinarily important in terms of their impact on human health," said Spiegel.

The study has been published online in the Journal of the American Chemical Society
For the Joint Academic Classification of Subjects system, see Joint Academic Classification of Subjects.

The Journal of the American Chemical Society (usually abbreviated as J. Am. Chem. Soc.
. (ANI)

Copyright 2009 Asian News International The Asian News International (ANI) agency provides multimedia news to China and 50 bureaus in India. It covers virtually all of South Asia since its foundation and presently claims, on its official website, to be the leading South Asia-wide news agency.  (ANI) - All Rights Reserved.

Provided by Syndigate.info an Albawaba.com company
COPYRIGHT 2009 Al Bawaba (Middle East) Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2009 Gale, Cengage Learning. All rights reserved.

 Reader Opinion

Title:

Comment:



 

Article Details
Printer friendly Cite/link Email Feedback
Publication:Asian News International
Date:Nov 6, 2009
Words:270
Previous Article:Ponting, Taylor pitch for Hughes inclusion in series against Windies.
Next Article:'Optical biopsy' could take over invasive biopsies for breast cancer detection.
Topics:



Related Articles
PSMA LICENSES ALPHAVAX ARV FOR PROSTATE CANCER VACCINE.
CEL-SCI obtains three new HIV patents.(intellectual property protection for C strain (clade) of the HIV virus)(Brief Article)
Immune cells target cancerous tissue. (Vaccine Power).(prostate cancer vaccine)(Brief Article)
NIH AWARDS HIV GRANT TO ANTIGEN EXPRESS FOR DNA VACCINE.
Immune Response licenses Hybridon's AMPLIVAX vaccine adjuvant.
HYBRIDON'S OLIGONUCLEOTIDES SHOW POTENT ADJUVANT ACTIVITY.
Monogram Biosciences Provides Progenics Pharmaceuticals with HIV Assays for Use in Clinical Trials.
Vaccine prevents prostate cancer in mice.(JUST IN)(Brief article)
Dendritic Cells in the Treatment of Prostate Cancer.(Report)
BIT Life Sciences' 1st Annual World Congress of Immunodiseases and Therapy 2010 (WCIT-2010) Calling for Participants

Terms of use | Copyright © 2009 Farlex, Inc. | Feedback | For webmasters | Submit articles